Summary
￭ IPG0916 is a selective and potent, pre-clinical antibody antagonist designed to target CCR6, a key chemokine receptor that drives Th17-mediated autoimmune diseases such as psoriasis.
￭ Unlike traditional, broad-acting immunosuppressants, IPG0916 offers a highly specific mechanism aimed at preventing the migration of pathogenic Th17 cells to inflammatory sites.
￭ As a targeted biologic with the potential for combination therapy and a strong pre-clinical profile, IPG0916 is positioned to enter a significant and growing global market for autoimmune therapies, addressing the need for safer and more effective treatment options.
Mechanism of Action
￭ Th17 cells are a critical subset of T cells that produce pro-inflammatory cytokines (e.g., IL-17, IL-22), which are key mediators of tissue damage in many autoimmune diseases. The CCR6 receptor is predominantly expressed on these Th17 cells and acts as a homing signal, guiding them to sites of inflammation by interacting with its ligand, CCL20.
￭ IPG0916 is an antibody that specifically binds to CCR6, blocking its interaction with CCL20. This action effectively prevents Th17 cells from migrating and accumulating in target tissues. By reducing the local concentration of these pathogenic cells, IPG0916 is designed to decrease the secretion of inflammatory cytokines, thereby alleviating the inflammatory response at the core of the disease. Pre-clinical data confirms that IPG0916 potently blocks CCR6-mediated intracellular signaling with nanomolar IC50.
Key Differentiation
￭ High Specificity: IPG0916 specifically targets CCR6-expressing Th17 cells, which is anticipated to reduce the risk of global immunosuppression and its associated side effects, a common limitation of traditional therapies.
￭ Combination Potential: Its focused mechanism makes it an ideal candidate for combination therapy with other biologics, such as anti-TNF-α or anti-IL-17 antibodies, to achieve a more profound and comprehensive therapeutic effect.
￭ Strong Pre-clinical Profile: IPG0916 is a potent human CCR6 antagonist that binds with high affinity to both human and monkey CCR6, and has demonstrated stability under stress conditions, indicating a robust product profile.
￭ Competitive Landscape: IPG0916 ranked Top 3 in the clinical progress globally, positioning favorably as it advances toward the clinic.
Current Development & Status
￭ IPG0916 is in the pre-clinical phase. We are advancing the IND-enabling studies, which are expected to be conducted in early 2026.
Cpyright © 2023 Nanjing Immunophage Biotech Co.,Ltd
All Rights Reserved. 苏ICP备2022026466号-1 
苏公网安备 32011202000830号
Back